Ovarian Cancer Pipeline Review, H1 2018 - Therapeutic Assessment of 300 Companies & Drug Profiles - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 26, 2018--The “Ovarian Cancer - Pipeline Review, H1 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Ovarian Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 15, 152, 147, 11, 209, 28 and 12 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 12, 15, 47 and 8 molecules, respectively.
Ovarian Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:Introduction Ovarian Cancer - Overview Ovarian Cancer - Therapeutics Development Ovarian Cancer - Therapeutics Assessment Ovarian Cancer - Companies Involved in Therapeutics Development Ovarian Cancer - Drug Profiles Ovarian Cancer - Dormant Projects Ovarian Cancer - Discontinued Products Ovarian Cancer - Product Development Milestones Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/wjcnvd/ovarian_cancer?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180926006009/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Women’s Health,Ovarian Cancer Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/26/2018 04:21 PM/DISC: 09/26/2018 04:21 PM